Coming Soon
UK GPhC-Registered Pharmacy
Wegovy® TabletsSemaglutide — Once Daily The same clinically proven semaglutide as the Wegovy® injection — now in a convenient once-daily pill. No needles. No pens. Prescribed online by UK-registered clinicians.
GPhC-registered pharmacy
UK-licensed prescribers
Discreet tracked delivery
Genuine Novo Nordisk product
~14%
average body weight loss
with Wegovy® tablet 25 mg 64-week clinical study alongside a reduced-calorie diet and increased physical activity. ~14% weight loss vs ~2.4% with placebo.
with Wegovy® tablet 25 mg 64-week clinical study alongside a reduced-calorie diet and increased physical activity. ~14% weight loss vs ~2.4% with placebo.
8 in 10
patients lost ≥5% of body weight
1 in 4
patients lost ≥20% of body weight
About the Medicine
What is the Wegovy® Tablet (semaglutide)?
Wegovy® is now available as a once-daily prescription tablet containing semaglutide — the same active ingredient as the Wegovy® injection. It is designed to support weight loss and long-term weight management in adults who meet specific clinical criteria.
Wegovy® tablets are taken once daily and are prescribed alongside a reduced-calorie diet and increased physical activity. Like the injection, the tablet belongs to the class of medicines known as GLP-1 receptor agonists (GLP-1 RAs), which mimic a naturally occurring hormone that regulates appetite and calorie intake.
In the UK, Wegovy® is only available following a clinical assessment to ensure it is safe and appropriate for your individual health profile. At Happy Pharmacy, Wegovy® tablets are prescribed by qualified clinicians and dispensed by a UK GPhC-registered pharmacy.
~14%
average body weight loss at 25 mg dose
Once
daily tablet — no injections, no needles
94%
similarity to your body's own GLP-1 hormone
64 wks
duration of pivotal clinical study
Tablet vs Injection — what's the difference?
Both contain semaglutide and work via the same GLP-1 mechanism. The tablet is taken once daily orally; the injection once weekly subcutaneously. The injection currently has the cardiovascular risk reduction indication. Your prescriber can advise which is more appropriate for you.
Why Wegovy® Tablets
Benefits you need to know about
Beyond weight loss, the Wegovy® tablet shares the same clinically proven benefits as the injection — without needles.
No needles — a daily tablet instead
For patients who prefer not to inject, the Wegovy® tablet offers the same active ingredient in a convenient once-daily oral form. No pens, no needles, no sharps disposal required.
Clinically proven weight loss
In a 64-week clinical study, adults taking the Wegovy® tablet (25 mg) lost an average of 14% of their body weight — approximately 33 lb (around 15 kg) based on a starting weight of 235 lb.
Proven cardiovascular protection
Wegovy® is the only weight management medicine with a cardiovascular risk reduction indication. The SELECT trial showed a 20% relative risk reduction in major cardiovascular events, independently of weight lost.
Regulates appetite naturally
Semaglutide shares 94% sequence similarity with the body's own GLP-1 hormone, which naturally regulates appetite and calorie intake. Targets key areas of the brain to reduce hunger and increase feelings of fullness.
Additional health improvements
Adults using the Wegovy® tablet also experienced improvements in waist size, cholesterol levels, and blood sugar control alongside primary weight loss. Wegovy® is not specifically approved to treat these conditions.
Clinical Evidence
Clinically proven Wegovy® tablet results
In a 64-week medical study, adults taking Wegovy® tablets alongside a reduced-calorie diet and increased physical activity lost an average of 14% of their body weight — equivalent to approximately 33 lb based on a starting weight of 235 lb. In comparison, those taking placebo lost around 2.4%, or approximately 6 lb.
Around 8 in 10 patients (76%) taking the Wegovy® tablet achieved 5% or more weight loss, compared with 31% taking placebo. Additionally, 28% of adults (about 1 in 4) achieved 20% or more weight loss, compared with just 3% on placebo.
~14%
average body weight loss (64-week study, 25 mg)
2.4%
average weight loss with placebo (vs ~14% on Wegovy®)
76%
of adults achieved ≥5% weight loss (vs 31% placebo)
28%
of adults achieved ≥20% weight loss (vs 3% placebo)
Study Details
The 64-week study included 307 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related medical problem, including high blood pressure or high cholesterol. Adults with type 2 diabetes were excluded. 205 adults received Wegovy® tablets once daily and 102 received placebo, both alongside dietary and activity guidance.
Am I Eligible?
Who is the Wegovy® tablet for?
Wegovy® tablets are prescribed for adults who meet specific clinical criteria based on BMI and overall health. Eligibility is confirmed during your free online consultation.
This list is not exhaustive. Final suitability is always confirmed following clinician review during your online consultation. Please refer to the Wegovy® SmPC for full prescribing information.
✓ You may be eligible if…
- BMI of 30 or above (clinically obese)
- BMI of 27 or above with a weight-related health condition (e.g. high blood pressure, high cholesterol, pre-diabetes)
- Aged 18 or over
- Not pregnant or breast-feeding
- Able to follow dietary and lifestyle guidance
✗ May not be suitable if…
- You are pregnant, breast-feeding, or trying to conceive
- You have type 1 diabetes
- You are already taking another GLP-1 receptor agonist
- You have a history of pancreatitis
- You have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2
- You have a known hypersensitivity to semaglutide
How to Take It
How to take the Wegovy® tablet
The Wegovy® tablet is taken once daily, every day. Follow the simple Sip & Go routine each morning for the medicine to work as intended.
① SIP
Wake up & take your tablet
Take 1 Wegovy® tablet on an empty stomach with a small sip of plain water (up to 120 ml / 4 oz). Do not take with any other liquid.
② GO
Start your morning
Wait at least 30 minutes before eating food, drinking any other beverages (including coffee or tea), or taking other oral medications.
⚠ Important: Do NOT do the following
- Crush, cut, chew, or dissolve the tablet
- Take more than 1 tablet each day
- Take with any liquid other than plain water
- Store tablets outside the original bottle
- Share your medication with others
💊 If you miss a dose
Simply skip that day's tablet and resume the following morning at your usual time. Do not take two tablets to make up for a missed dose.
🌡 Storing your tablets
Keep at room temperature (20°C–25°C / 68°F–77°F) in a dry place. Store in the original closed bottle with the cap tightly shut. Keep out of reach of children.
Treatment Plan
Wegovy® tablet dosage and treatment timeline
Treatment begins at the lowest dose and is increased every 30 days, as tolerated, until the maximum maintenance dose of 25 mg once daily is reached. This gradual escalation gives your body time to adjust and helps minimise side effects.
Dosing schedule is indicative. Your prescriber may keep you at one dose for longer than 30 days to allow your body more time to adjust. Individual results may vary.
| Days | Dose | Purpose | Stage |
|---|---|---|---|
| Days 1–30 | 1.5 mg once daily | Starting dose — body adjustment | Starter |
| Days 31–60 | 3 mg once daily | First increase — appetite control improves | Titration |
| Days 61–90 | 7 mg once daily | Gradual step-up for continued progress | Titration |
| Days 91–120 | 14 mg once daily | Higher dose for additional appetite support | Titration |
| Day 121+ | 25 mg once daily | Maximum maintenance dose — full treatment effect | Maintenance |
Safety Information
Wegovy® tablet side effects
Like all prescription medicines, Wegovy® can cause side effects. Most are mild to moderate and improve over time, particularly during dose escalation. This information does not replace the full SmPC or your prescriber's advice.
⚠ Very common (≥1 in 10 patients)
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain
- Headache
- Fatigue
⚠ Common (1–10 in 100 patients)
- Dizziness
- Altered taste
- Heartburn
- Bloating
- Hair loss
- Injection site reactions
- Gallstones
Serious / uncommon — seek urgent medical advice
For urgent symptoms contact NHS 111. For emergencies call 999. Report adverse events to the MHRA via the Yellow Card scheme or to Novo Nordisk on 0800 023 2573.
- Acute pancreatitis — persistent, severe abdominal pain; stop treatment and seek urgent help
- Severe allergic reaction / anaphylaxis — swelling of face, lips, or throat; difficulty breathing
- Changes in vision — seek urgent ophthalmology review
- Increased resting heart rate — report to your prescriber
FAQs
Frequently asked questions
In a 64-week clinical study, adults taking the Wegovy® tablet alongside a reduced-calorie diet and increased physical activity lost an average of 14% of their body weight — approximately 33 lb based on a starting weight of 235 lb. Around 76% achieved at least 5% weight loss, and 28% achieved 20% or more. Individual results vary.
Both contain the same active ingredient — semaglutide — and work via the same GLP-1 mechanism. The key difference is delivery: the tablet is taken once daily by mouth, whereas the injection (FlexTouch® pen) is administered once weekly subcutaneously. The injection currently has additional indications including cardiovascular risk reduction. Your prescriber can advise which is more appropriate for you.
Wegovy® is not anticipated to reduce the effectiveness of oral contraceptives. However, if you experience severe vomiting or diarrhoea, this could theoretically affect pill absorption — follow your pill's missed-dose guidance or seek pharmacist advice. Women of childbearing age are recommended to use contraception whilst taking semaglutide.
Wegovy® is a prescription-only medicine (POM) in the UK and must only be purchased from a GPhC-registered pharmacy following a clinician-approved consultation. At Happy Pharmacy, your consultation is reviewed by a UK-registered prescriber. Never buy Wegovy® from unregulated websites or social media sellers — counterfeit products carry serious health risks.